Power of Two: Perspective, BMS Partner to Study VMT01 Plus Nivolumab in MC1R-Positive Metastatic Melanoma
Perspective Therapeutics, Inc. is partnering with Bristol Myers Squibb (BMS) to evaluate [212Pb]VMT01 in combination with nivolumab (Opdivo, BMS) in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. VMT01 is a proprietary clinical-stage low molecular weight peptide that is targeted to the melanocortin subtype 1 receptor (MC1R) which is over-expressed […]